Command Palette

Search for a command to run...

Clinical Trials · NCT02527200

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

CompletedPhase 3Liraglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
56
Start date
Nov 2015
Locations
32 sites, 8 countries
Primary endpoint
Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks
View Liraglutide compound reference